Early Changes in Hyppocampal Neurogenesis Induced by Soluble Aβ1-42 Oligomers


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Alzheimer’s disease (AD) is characterized by the loss of neurons, the accumulation of intracellular neurofibrillary tangles and extracellular amyloid plaques in the brain. However, contradicting data exist on differences in neurogenesis at the onset of the disease or before the formation of amyloid plaques. Taking into consideration growing awareness of the importance of the pre-symptomatic phase in neurodegenerative diseases in the context of early diagnosis and pathogenesis, we have analyzed critical periods of adult hippocampal neurogenesis at the early stage under the action of soluble forms of amyloid-beta (Aβ1-42). Using the mouse AD model induced by injection of soluble Aβ oligomers we investigated proliferation, migration, and neuronal cells survival. The injection of Aβ1-42 oligomers caused a decrease in cell proliferation in the mouse hippocampus. Despite preservation of the neuroblast pool in animals treated with Aβ injection, the process of radial migration impaired, and apoptosis increased. Thus, our results demonstrate that Aβ administration impaired critical stages of neurogenesis including progenitor cells, neuroblast migration, integration of immature neurons, and survival of neurons under application of soluble beta-amyloid oligomers. The data obtained indicate the decline in proliferation rate in the subgranular zone, which is accompanied by ectopic differentiation and disturbed migration, producing, apparently, abnormal neurons that have lower survival rates. That could lead to a decrease in the number of mature neurons and in the number of cells in the granular layer of the dentate gyrus.

Sobre autores

Yu. Komleva

Department of Biochemistry, Medical, Pharmaceutical, and Toxicological Chemistry, Prof. Voino-Yasenetsky Krasnoyarsk State Medical University; Research Institute of Molecular Medicine and Pathobiochemistry, Prof. Voino-Yasenetsky Krasnoyarsk State Medical University

Autor responsável pela correspondência
Email: yuliakomleva@mail.ru
Rússia, ul. Partizana Zheleznyaka 1, Krasnoyarsk, 660022; Krasnoyarsk

O. Lopatina

Department of Biochemistry, Medical, Pharmaceutical, and Toxicological Chemistry, Prof. Voino-Yasenetsky Krasnoyarsk State Medical University; Research Institute of Molecular Medicine and Pathobiochemistry, Prof. Voino-Yasenetsky Krasnoyarsk State Medical University

Email: yuliakomleva@mail.ru
Rússia, ul. Partizana Zheleznyaka 1, Krasnoyarsk, 660022; Krasnoyarsk

Ya. Gorina

Department of Biochemistry, Medical, Pharmaceutical, and Toxicological Chemistry, Prof. Voino-Yasenetsky Krasnoyarsk State Medical University; Research Institute of Molecular Medicine and Pathobiochemistry, Prof. Voino-Yasenetsky Krasnoyarsk State Medical University

Email: yuliakomleva@mail.ru
Rússia, ul. Partizana Zheleznyaka 1, Krasnoyarsk, 660022; Krasnoyarsk

A. Chernykh

Research Institute of Molecular Medicine and Pathobiochemistry, Prof. Voino-Yasenetsky Krasnoyarsk State Medical University

Email: yuliakomleva@mail.ru
Rússia, Krasnoyarsk

A. Shuvaev

Research Institute of Molecular Medicine and Pathobiochemistry, Prof. Voino-Yasenetsky Krasnoyarsk State Medical University

Email: yuliakomleva@mail.ru
Rússia, Krasnoyarsk

A. Salmina

Department of Biochemistry, Medical, Pharmaceutical, and Toxicological Chemistry, Prof. Voino-Yasenetsky Krasnoyarsk State Medical University; Research Institute of Molecular Medicine and Pathobiochemistry, Prof. Voino-Yasenetsky Krasnoyarsk State Medical University

Email: yuliakomleva@mail.ru
Rússia, ul. Partizana Zheleznyaka 1, Krasnoyarsk, 660022; Krasnoyarsk

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Pleiades Publishing, Ltd., 2018